Show simple item record

dc.contributor.authorHernando, Cubero J
dc.contributor.authorGrande, E
dc.contributor.authorGauna, DC
dc.contributor.authorIbrahim, T
dc.contributor.authorFazio, N
dc.contributor.authorLopez, C
dc.contributor.authorTeule, A
dc.contributor.authorValle, Juan W
dc.contributor.authorAlonso, V
dc.contributor.authorMolina-Cerrillo, J
dc.contributor.authorTafuto, S
dc.contributor.authorCustodio, A
dc.contributor.authorTrejo, L
dc.contributor.authorCasteras, A
dc.contributor.authorKopp, RM
dc.contributor.authorMiqueo, C
dc.contributor.authorHerrera, MR
dc.contributor.authorGarcia-Carbonero, R
dc.contributor.authorSalazar, R
dc.contributor.authorCapdevila, J
dc.date.accessioned2019-12-09T17:23:31Z
dc.date.available2019-12-09T17:23:31Z
dc.date.issued2019en
dc.identifier.citationHernando Cubero J, Grande E, Castellano Gauna D, Ibrahim T, Fazio N, Lopez C, et al. 1387P Differences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumours (NETs). Annals of Oncology. 2019;30(Supplement_5):567.en
dc.identifier.doi10.1093/annonc/mdz256.007en
dc.identifier.urihttp://hdl.handle.net/10541/622592
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdz256.007en
dc.titleDifferences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumours (NETs)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMedical Oncology, Vall d'Hebron University Hospital, Barcelonaen
dc.identifier.journalAnnals of Oncologyen
refterms.dateFOA2020-01-21T20:13:01Z


Files in this item

Thumbnail
Name:
mdz256.007.pdf
Size:
76.03Kb
Format:
PDF
Description:
From UNPAYWALL. Conference abstract

This item appears in the following Collection(s)

Show simple item record